《生命科学》 2013, 25(4): 347-351
摘 要：摘 要：内源性大麻系统由大麻受体、内源性大麻素和内源性大麻素的降解酶构成。现已公认的大麻受体包括大麻1 型(cannabinoid receptor subtype 1， CB1) 受体和大麻2 型(cannabinoid receptor subtype 2， CB2) 受体，它们广泛分布于中枢和外周神经系统，在认知、情感、动机、痛觉、内分泌、免疫等很多方面发挥重要作用。近几年的一些研究表明，精神分裂症与内源性大麻系统功能失调，尤其是CB1 受体的过度激活密切相关。因此，大麻受体可能成为治疗精神分裂症的新靶点。已经对几种CB1 受体拮抗剂的抗精神分裂症效果进行了动物实验和临床研究，并取得了一些进展。将对近几年关于内源性大麻系统与精神分裂症的研究进展进行简要综述。
关键词：大麻受体；精神分裂症；拮抗剂
Abstract: Abstract: The endocannabinoid system is composed of cannabinoid receptor， endocannabinoids and their degrading enzyme. Till now， two cannabinoid receptors， designated as CB1 and CB2， have been recognized. They are widely distributed in central nervous system and peripheral system， and play critical roles in many aspects of physiology， including cognition， emotion， motivation， algesia， endocrine， immunity etc. Recent evidence indicated that dysregulation of the endocannabinoid system， especially the overactivity of CB1 receptor， is involved in the pathogenesis of schizophrenia. Based on this hypothesis， cannabinoid receptor has been taken into account as a new target for schizophrenia. Several researches have indicated CB1 receptor antagonists have antipsychotic properties. In this article， we will briefly review the latest progress in this field.
Key words: cannabinoid receptor; schizophrenia; antagonists
